Compare GIC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIC | XERS |
|---|---|---|
| Founded | 1949 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1996 | 2021 |
| Metric | GIC | XERS |
|---|---|---|
| Price | $33.54 | $8.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 133.4K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | 17.09 | ★ 100.00 |
| EPS | ★ 0.42 | 0.01 |
| Revenue | ★ $1,379,100,000.00 | $49,590,000.00 |
| Revenue This Year | $5.72 | $34.37 |
| Revenue Next Year | $4.60 | $22.86 |
| P/E Ratio | ★ $79.98 | $813.00 |
| Revenue Growth | 4.80 | ★ 142.67 |
| 52 Week Low | $26.40 | $4.87 |
| 52 Week High | $38.53 | $10.08 |
| Indicator | GIC | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 65.61 |
| Support Level | $33.39 | $6.86 |
| Resistance Level | $34.14 | $8.46 |
| Average True Range (ATR) | 0.94 | 0.33 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 58.57 | 56.33 |
Global Industrial Co is a value-added industrial distributor. The company distributes a wide range of industrial and maintenance, repair, and operations (MRO) products to customers across North America, including storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, food service and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw material.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.